Trial · NCT04134416
Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia
NCT04134416, Phase 3, Completed, University of Malaga
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia. Trials, record NCT04134416. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04134416
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia
- NCT number
- NCT04134416
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Malaga
- Conditions
- Aphasia, Stroke
- Interventions
- Donepezil, Intensive-Language Action Therapy, Transcranial direct current stimulation
- First posted
- 2019-10-22
- Last updated
- 2020-11-05
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Western Aphasia Battery (WAB) | Each participant will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess major clinical aspects of language function: information content, fluency, auditory comprehension, repetition and naming. Changes from Baseline in Western Aphasia Battery scores at 8, 10 and 26 weeks. Minimum and maximum values: 0-100 points. Higher scores mean better outcome. |
| Primary | Communicative Activity Log (CAL) | Each participant/ main carer will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess communicative behavior in the everyday life of patients. Changes from Baseline in CAL scores at 8, 10 and 26 weeks. Minimum and maximum values: 0-90 points (0-40 points for quality of communication; 0-40 points for amount of communication). Higher values mean better outcome. |
| Primary | Stroke Aphasia Depression Questionnaire (SADQ-10) | Each participant/ main carer will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess depressive symptomatology in persons with post-stroke aphasia. Changes from Baseline in SADQ-10 scores at 8, 10 and 26 weeks. Minimum and maximum scores: 1-30 points. Lower values mean better outcome. |
| Primary | Stroke and Aphasia Quality of Life Scale 39 (SAQOL-39) | Each participant/ main carer will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess Quality of Life in persons with post-stroke aphasia. Changes from Baseline in SAQOL-39 scores at 8, 10 and 26 weeks. Minimum and maximum scores: 1-85 (Physical scale); 1-35 (Communication scale); 1-55 (Psychosocial scale); 1-20 (Vitality scale); 1-5 (Total mean scale). Higher values mean better outcome. |
| Secondary | Mini Mental State Examination (MMSE) | Each participant will be evaluated at week 0 (baseline). | To assess cognitive impairment in persons with post-stroke aphasia. Minimum and maximum scores: 1-30 points. Higher values mean better outcome. |
| Secondary | Trail-Making Test, parts A & B (TMT) | Each participant will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess executive functions in individuals affected by post-stroke aphasia. Changes from Baseline in TMT scores at 8, 10 and 26 weeks. The participant has to finish both parts as quickly as possible, with the time taken to complete the test being used as the primary performance metric. Lower completion time means better outcome. |
| Secondary | Digit Span Test from the Wechsler Adult Intelligence Scale (WAIS) | Each participant will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess immediate memory in persons with post-stroke aphasia. Changes from Baseline in Digit scores at 8, 10 and 26 weeks. Minimum and maximum scores: 3-9. Higher values mean better outcome. |
| Secondary | Attention Network Test (ANT). | Each participant will be evaluated at week 0 (baseline), 8, 10 and 26. | To assess three attentional networks: alerting, orienting, and executive control in in persons with post-stroke aphasia. Changes from Baseline in ANT scores at 8, 10 and 26 weeks. Efficiency of the alerting network is examined by changes in Reaction Time (RT) resulting from a warning signal. Efficiency of orienting is examined by changes in RT that accompany cues indicating where the target will occur. The efficiency of the executive network is examined by requiring the subject to respond by pressing two keys indicating the direction (left or right) of a central arrow surrounded by congruent, incongruent or neutral flankers. Lower reaction time and higher congruent responses mean better outcome. |
| Secondary | Raven´s Colored Progressive Matrices (RPM), set A, B & AB | Each participant will be evaluated at week 0 (baseline). | To assess abstract reasoning in persons with post-stroke aphasia. Evaluation at baseline. Minimum and maximum score: 0-36. Higher scores mean better outcome. |
| Secondary | Cognitive Reserve Questionnaire. | Each participant will be evaluated at week 0 (baseline) | To assess the cognitive reserve of persons with post-stroke aphasia. Evaluation at baseline. Minimum and maximum scores: 0-25. Higher values mean better outcome. |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Attention Network Test | Secondary outcome | ConductCognition |
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Matrix Reasoning | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04134416
GET https://conductscience.org/api/trials/v1/NCT04134416/registered?page=2